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The binding of drugs with serum proteins and binding agents such as human serum albumin, a1-acid
glycoprotein, and lipoproteins is an important process in determining the activity and fate of many
pharmaceuticals in the body. A variety of techniques have been used to study drug interactions with
serum proteins, but there is still a need for faster or better methods for such work. High-performance
liquid chromatography (HPLC) is one tool that has been utilized in many formats for these types of
measurements. Advantages of using HPLC for this application include its speed and precision, its
ability to be automated, its good limits of detection, and its compatibility with a wide range of assay
formats and detectors. This review will discuss various approaches in which HPLC can be employed for
the study of drug-protein interactions. These techniques include the use of soluble proteins in zonal
elution and frontal analysis methods or vacancy techniques such as the Hummel-Dreyer method. Zonal
elution and frontal analysis methods that make use of immobilized proteins and high-performance
affinity chromatography will also be presented. A variety of applications will be examined, ranging
from the determination of free drug fractions to the measurement of the strength or rate of a drugprotein interaction. Newer developments that will be discussed include recent work in the creation of
novel mathematical approaches for HPLC studies of drug-protein binding, the use of HPLC methods
for the high-throughput screening of drug-protein binding, and the creation and use of affinity
monoliths or affinity microcolumns for examining drug-protein systems.

1. Introduction
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The binding of drugs with proteins in serum (i.e., the serum
proteome) is an important process in determining the eventual
activity and fate of many pharmaceutical agents in the body.1–13
Fig. 1 shows a general model for this type of interaction, as
illustrated for the formation of a 1 : 1 reversible complex between
a drug and a serum protein. In this model, Ka is the association
equilibrium constant for the formation of a drug-protein
complex, while ka and kd are the corresponding association and
dissociation rate constants for this process.1,7 This type of
interaction frequently involves common serum transport
proteins and binding agents such as human serum albumin
(HSA), a1-acid glycoprotein (AGP), and lipoproteins (e.g., highdensity lipoprotein, or HDL, and low-density lipoprotein, or
LDL).1–8 In some cases more specific binding agents can take part
in these interactions. An example of this latter situation is the
binding of steroids with corticosteroid-binding globulin
(CBG).7,14
These drug-protein interactions are often significant, with
approximately 43% of the 1500 most common drugs having at
least 90% binding to proteins in serum.13 For instance, these
interactions can affect the amount of the free, or non-complexed,
form of a drug in the circulation and can have a large effect on
the distribution, effective activity, excretion, and metabolism of
a drug.1–4 The direct or indirect competition between drugs and
other solutes for binding sites on serum proteins can not only be
Anal. Methods, 2011, 3, 1449–1460 | 1449

an important source of drug-drug interactions but can lead to
interactions between drugs and endogenous agents such as fatty
acids, which also bind to some serum proteins.1–8 In addition, the
binding of drugs with serum proteins can improve the overall
solubility of a hydrophobic drug within the circulation.9 Because
the binding of some chiral drugs with proteins can be stereoselective in nature, it is further possible that these interactions in
serum may affect the apparent activities for different forms of
a chiral drug in the body.5,9,11,12
A variety of techniques have been used in the past to study
drug interactions with serum proteins. Ultrafiltration and equilibrium dialysis are the most common methods utilized for this
type of work.15,16 In addition, fluorescence spectroscopy,18
absorption spectroscopy,18 X-ray crystallography,6,19,20 nuclear
magnetic resonance (NMR) spectroscopy,21,22 capillary electrophoresis,23–25 and surface plasmon resonance26 have been
employed. However, there is still a growing need for general
methods that can provide faster and more convenient
approaches for the analysis and characterization of drug-protein
binding in serum and related samples.
High-performance liquid chromatography (HPLC) is one tool
that has been used in many formats for such work. Some
attractive features of HPLC for this application include its speed
and precision, its ability to be automated and conducted with
common equipment, its good limits of detection and efficiency,
and its compatibility with a wide range of assay formats and
detectors.7–10 The purpose of this review is to examine the various
approaches in which HPLC can be employed for the study of
drug-protein interactions with both soluble drugs and proteins or
with immobilized forms of these agents. An overview of these
techniques will be presented and various applications will be
described for these methods.

2. Zonal elution methods using soluble proteins
One approach that can be employed in HPLC to study drugprotein interactions is to use zonal elution to separate the free
and protein-bound fractions of a drug in a sample. In this case,
a small sample of a drug-protein mixture is injected onto

Fig. 1 General model for the reversible binding of a drug with a protein
in blood or serum. The model shown here is for the formation of a 1 : 1
complex between the protein and drug, as described by the association
equilibrium constant (Ka) and corresponding association rate constant
(ka) and dissociation rate constant (kd). Similar reactions can be written
for multi-site drug-protein interactions or mixed-mode interactions.

a column which has different retention for the drug and drugprotein complex. If little to no dissociation occurs for the drugprotein complex during the experiment, the measured amount of
drug in the free or protein-bound fraction that elutes from the
column can be used to determine the extent of drug-protein
binding in the sample and the equilibrium constant for this
interaction.7
The earliest use of this approach involved the injection of small
samples onto columns that contained size-exclusion supports.27
In this type of experiment, the drug-protein complex eluted first,
followed later by the free drug fraction. This approach has been
reported to require an association equilibrium constant for
a drug-protein complex that is greater than 107 M1, which would
generally provide only a small level of dissociation as the
complex passes through the size-exclusion column.7,28,29 For
instance, this method has been used to study the interaction
between prednisolone and CBG, which has a relatively large
association equilibrium constant (Ka ¼ 3  107 M1), but was not
successful when used to examine the binding of prednisolone
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with HSA (Ka ¼ 2  103 M1).29 HPLC size-exclusion columns
have been used to examine the binding of ATX-S10(Na) to highdensity lipoprotein (HDL) and to serum albumin, as well as other
serum proteins.30 In a similar manner, gel fitration has been
utilized to study the binding of cosalane to HSA and AGP.31 In
this latter study, gel filtration was further used to examine the
competition between cosalane and various site-selective probes
for known binding sites on HSA.31
It is also possible to examine drug-protein interactions by
injecting a small sample of a drug onto a size-exclusion column in
the presence of a known concentration of protein in the mobile
phase. As the drug binds to the protein, a drug-protein complex
will form and there will be a decrease in the drug’s observed
retention. The global association equilibrium constant for the
drug-protein interaction can then be determined by comparing
the analyte’s retention times in the presence and absence of
protein in the mobile phase.7,10 This method has been used to
examine the binding of HSA to warfarin, furosemide, phenylbutazone, tryptophan, and omeprazole.32–34 In order to use this
approach to study drug-protein binding, it is necessary to have
association and dissociation rates for the interaction that are fast
enough to allow a local equilibrium to be established between the
drug and protein as these components pass through the column.
It is also necessary for the amount of injected drug to be small
compared to the amount of protein in the mobile phase.32,33
Zonal elution methods can further be employed with internal
surface reversed-phase (ISRP) columns to perform peak-splitting
measurements of drug-protein interactions.7,35–39 The ISRP
columns utilized in this approach consist of a reversed-phase
stationary phase that is located only within the pores of the
support. When a drug-protein mixture is injected onto this type
of support, the drug-protein complex is excluded from the pores
while the free drug fraction is allowed to enter the pores and
interact with the reversed-phase sites. A peak-splitting effect can
then arise when dissociation of the drug-protein complex occurs
at a rate similar to the timescale of the separation. This effect
results in a situation where two drug peaks elute from the
column. The first, broad peak corresponds to the drug that was
originally bound to the protein and the second, sharper peak
corresponds to the original free drug fraction. The result is
a chromatogram in which both the free and protein-bound
fractions of a drug can be determined within a single run.
Systems examined by this approach have included mixtures of
HSA with phenytoin,35,36 imirestat,36 or warfarin37 and mixtures
of warfarin with bovine serum albumin (BSA).38,39
Several recent reports have used immobilized antibodies and
high-performance immunoaffinity chromatography to measure
free drug fractions.40–44 In one of these studies, ultrafast immunoextraction was used to examine the free drug fractions in
warfarin/HSA mixtures.40 In this study, sandwich microcolumns
containing a 1.1 mm layer of a support with anti-warfarin antibodies were used to extract the free warfarin fraction in about
180 ms. This column was then used in series with ISRP columns
to determine the remaining fraction of warfarin that was bound
to HSA. The results gave good agreement with those predicted
by solution-phase measurements.40
Other studies have used ultrafast immunoextraction with
HPLC-based displacement immunoassays to measure the free
fractions of thyroxine or phenytoin in serum.41,42 In this work,
This journal is ª The Royal Society of Chemistry 2011

a sample containing the free and protein-bound forms of the
analyte was injected onto a small immobilized antibody column
that contained a reversibly-bound and labeled analog of the
analyte, as illustrated in Fig. 2. As the sample passed through
the column, the free fraction of the analyte displaced some of the
labeled analog. This displacement produced a peak for
the analog that was proportional to the amount of free analyte in
the original sample. Using this approach, the free fractions of
thyroxine and phenytoin were extracted from serum samples
within 90–100 ms, and the free concentrations of these analytes
were determined within 0.5–3.0 min of sample injection. Detection was achieved by using a chemiluminescent label and a postcolumn reactor in the case of thyroxine41 and a near-infrared
fluorescent label in the case of phenytoin.42 When used in the
analysis of serum, both methods gave good correlation versus
reference methods. The same approach has been used to examine
interactions between phenytoin and HSA.42 Similar work using
ultrafast immunoextraction and LC/MS detection has been
described in the analysis of free carbamazepine fractions.43,44

3. Frontal analysis using soluble proteins
Another common technique for examining drug-protein interactions in solution is frontal analysis.7,45–51 This approach was
first employed in 1964–1965 with soluble agents to examine
protein-protein binding45 and drug-protein interactions46 and is
still an important method for such measurements. Frontal
analysis using soluble proteins is different from the zonal elution
methods described in the previous section because a large volume
of a drug/protein mixture is used instead of a small plug of
sample.
A typical elution pattern that is seen during this type of frontal
analysis experiment is shown in Fig. 3, in which a mixture of
a low molecular weight drug and a protein is applied to a sizeexclusion column. In this situation, the drug will be able to enter
the pores of the support and will have a later elution time than

Fig. 2 Scheme for an immunoextraction/displacement assay for the
detection of a free drug fraction in a serum sample. Symbols: (N), labeled
analog of analyte; (l), unlabeled analyte from sample; ( ), binding
agent in a sample for the analyte; ( ), immobilized antibody. Reproduced with permission from ref. 42.
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the protein or drug-protein complex.48,49 Because a relatively
large sample volume has been applied, the column will produce
only a partial separation of these fractions. The elution profile
that is generated will ideally have several plateau regions.7,50 In
Fig. 3, the first plateau represents the non-complexed protein in
the original sample. This region in the chromatogram may or
may not be seen, depending on the detection method that is used
to monitor elution of the sample. The second plateau, or the
‘‘b band’’, represents the drug-protein complex. The final plateau
(i.e., the ‘‘g band’’) represents the free drug fraction at its equilibrium concentration.7,51 Information about the total and free
concentrations of the drug can be obtained from this profile. If
various concentrations of the drug are used in such an experiment, it is also possible to determine the equilibrium constants
and number of binding sites that are involved in the drug-protein
interaction.52–55
The use of HPLC with frontal analysis and soluble proteins
produces a method known as high-performance frontal analysis
(HPFA). This approach has been used in many reports to
examine drug-protein binding.7,28,51,56,57 For instance, HPFA has
been used to study the interactions of HSA with carbamazepine,
diazepam, fenoprofen, troglitazone, or warfarin.58–64 HPFA has
also been coupled with chiral HPLC columns for the separation
and measurement of the individual chiral forms of a drug within
the frontal analysis profile. This approach has been used to
examine the stereoselective binding of BOF-4272, fenoprofen,
ketoprofen, nilvadipine, and warfarin to proteins.37,64–68
The typical sample size in HPFA when using a size-exclusion
column is about 10–20 mL;7,51,59 however, the amount of sample
that is selected will be dependent on the degree of separation that
can be obtained between the free drug and drug-protein
complex.69–71 HPFA can also be conducted with ISRP columns,
which provides better resolution between the drug and drugprotein complex bands than size-exclusion columns and requires
only 80–400 mL of sample.7,51,64 In addition, HFPA can be
adopted for use with capillary electrophoresis, which needs even
less sample and which separates the drug and drug-protein bands
based on their differences in electrophoretic mobility.7,65,72–76

Fig. 3 Chromatogram obtained by high-performance frontal analysis
(HPFA) for a mixture of warfarin and HSA. The sample was a mixture of
100 mM warfarin plus 2 g L1 HSA that was injected onto a 30 cm 
3.9 mm I.D. size-exclusion column. Reproduced with permission from
ref. 60.
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In all of these methods, obtaining stable plateau regions,
particularly for the free drug band, can be difficult if strong
retention occurs between any of the sample components and the
stationary phase or walls of the capillary.7,28,65

4. Vacancy methods
Vacancy methods are a group of techniques that are based upon
the continual application of a mobile phase that contains either
the drug of interest or a combination of the drug and a protein.7
An injection is made of a sample that lacks one or more of these
components. As the sample plug passes through the column, the
local equilibrium between the drug and protein in the mobile
phase is perturbed. This effect produces a trough or vacancy
peak that occurs in response to a depletion of one of the mobile
phase components. The size of this peak is then used to determine
the amount of free drug or protein-bound drug that was present
in the mobile phase at equilibrium.7
The most common example of a vacancy technique is the
Hummel-Dreyer method.77 In this method, a solution containing
a known concentration of the drug of interest is passed through
a size-exclusion support. A sample of a protein is then injected
onto this system, causing one of two situations to occur. If the
protein does not bind to the drug, a single peak corresponding to
the protein will result. If reversible binding of the drug with the
protein is present, a portion of the free drug in the mobile phase
will be depleted and will become bound to the protein in the
sample. As a result, two peaks will appear as the sample passes
through a size-exclusion column. The first, positive peak will
represent the protein and drug-protein complex that is formed as
the protein passes through the column. The second, negative
peak will appear at the expected retention time for the drug and
will represent the depleted free fraction of the drug in the mobile
phase (see Fig. 4).7,77–79 The area of the negative peak can then be
used to measure the amount of drug that is bound by the protein
in the mobile phase. If this experiment is carried out at several
drug concentrations, the data can be used to obtain the binding
constants and the number of binding sites for the drug-protein
interaction.7,77–79
The Hummel-Dreyer method was originally developed in 1962
for use with low-performance size-exclusion columns.77 This
method was modified for work with HPLC in 1978 and was
validated by examining the binding that takes place between
HSA and warfarin.78 The HPLC version of the Hummel-Dreyer
method has since been used for the analysis of many drug-protein
systems. Examples of these systems have included the interactions of HSA with buspirone, ceftrixone, diazepam, isradipine,
phenobarbitol, phenytoin, propranolol, warfarin, carvedilol,
furosemide, phenylbutazone and pirprofen; the binding of AGP
with isradipine, propranolol, propanfenone, and carvedilol; and
the binding of HDL or LDL with amlodipine isradipine, or
propranolol.7,77–79 This method has typically been conducted by
using size-exclusion columns, but ion-exchange columns and
ISRP columns have also been used.7 In addition, this approach
has been modified for use in CE.7,71 The Hummel-Dreyer method
has been utilized in both binding studies78 and competition
studies, as has been shown in work with ISRP columns.7,79 In
addition, the Hummel-Dreyer technique has been employed with
both serum proteins and other proteins or binding agents
This journal is ª The Royal Society of Chemistry 2011

(e.g., enzymes, polysaccharides, and cyclodextrins).79 Two recent
examples that have illustrated the use of the Hummel-Dreyer
method with other binding agents have involved studies of
steroid-cyclodextrin inclusion complexes80 and the interactions
between tubulin and dolastatin 15.81
To relate the amount of a free drug and protein-bound drug to
the size of the vacancy peak in the Hummel-Dreyer method, the
system must be calibrated either internally or externally. When
using internal calibration, the protein is injected in the presence
of increasing concentrations of the drug while the total sample
volume is held constant.7,77,79 For external calibration, the size of
the vacancy peak is directly compared with the peak area that is
measured when the drug is injected onto the column in the
absence of any protein.7 One requirement in either calibration
method is the need to have a local equilibrium present between
the drug and protein, which requires the presence of sufficiently
fast association and dissociation kinetics on the time scale of the
experiment. Good resolution between the peaks for the proteinbound drug and the free drug fractions is also required.7,79
The equilibrium saturation method is another example of
a vacancy technique.82 This approach is similar to the HummelDreyer method in that a column containing a material such as
a size-exclusion support is utilized to resolve a drug and drugprotein complex from a mixture of these components.7 However,
in the equilibrium saturation method both the protein and drug
are used as mobile phase additives, and the sample contains only
the mobile phase buffer. The chromatogram that is produced
during sample injection will ideally contain two negative,
vacancy peaks. These two vacancy peaks appear at the retention
times for the drug-protein complex and the free form of the drug.
The size of these peaks can be used along with internal or
external calibration, as described in the previous paragraph, to
determine the free and protein-bound concentrations of the drug
in the mobile phase at equilibrium. If this experiment is carried
out in the presence of mobile phases that contain several different
drug-protein mixtures, it is possible to determine the association

equilibrium constants and number of binding sites that are
involved in the drug-protein interaction.82
The equilibrium saturation method has been used to study the
interactions of HSA with diazepam62 and to study the effects of
fatty acids82 and sodium dodecyl sulfate83 on the binding of HSA
with warfarin. Like the Hummel-Dreyer method, this approach
has been adapted for use in CE.7 The equilibrium saturation
method has also been used to study the competitive binding of
solutes to a protein for systems that have good resolution
between the peaks for the individual sample components.79
It is necessary in any application of the equilibrium saturation
method to have good resolution between the peaks for the free
drug and drug-protein complex and to have reasonably fast
kinetics for the drug-protein interaction on the time scale of the
study. Although the equilibrium saturation method requires
a larger amount of protein than the Hummel-Dreyer method,
drugs with lower solubility can be analyzed by the former
method because these drugs can bind to the protein in the mobile
phase, which will aid drug solubility.7

5. Zonal elution in HPAC
Various methods based on affinity chromatography can also be
used to study drug-protein interactions. Affinity chromatography is a type of liquid chromatography in which a biologicallyrelated agent (e.g., a protein or drug) is used as the stationary
phase.84,85 When HPLC media such as silica or monolithic
supports are used with an immobilized binding agent, the
resulting technique is known as high-performance affinity chromatography (HPAC).86–89 Affinity chromatography has long
been an important tool for the separation, purification and
analysis of compounds that can bind to immobilized agents such
as proteins, enzymes, dyes, nucleic acids and immobilized metal
ions.85 However, affinity chromatography and HPAC can also be
used to study biological interactions. The use of HPAC or
affinity chromatography for this purpose is referred to as

Fig. 4 Use of the Hummel-Dreyer method for examining the binding of warfarin with HSA. These experiments were conducted on a 5 cm long internal
surface reversed-phase (ISRP) column by injecting samples that contained either a buffer blank (top trace) or a sample of HSA (bottom trace) in the
presence of mobile phases that contained various, known concentrations of warfarin. The mobile phase concentrations of warfarin were as follows: (a)
81.1 mM, (b) 32.5 mM, (c) 8.1 mM, and (d) 1.6 mM. Reproduced with permission from ref. 61.
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analytical affinity chromatography, biointeraction affinity
chromatography or quantitative affinity chromatography.86–92
One advantage of using affinity chromatography to study
biological interactions is that the same immobilized binding
agent can often be used for a large number of sample injections.
This feature helps minimize the effects of batch-to-batch variations in the binding agent, resulting in good run-to-run precision,
and decreases the total amount of binding agent that is needed
for such studies. In addition, biointeraction studies carried out
by using HPAC can be automated and used in high-throughput
methods for drug-protein binding measurements.10
The proper use of affinity chromatography and HPAC for
binding studies requires that careful attention be given to the
preparation and treatment of the immobilized binding agent. In
work with HSA and AGP or closely-related proteins, it has been
shown that conditions for covalent attachment to a support can
often be found in which the immobilized form of the protein is
a good model for its soluble form.86,92–103 Similar results have been
noted for the covalent immobilization of lipoproteins within
HPAC columns.104 An alternative approach based on non-covalent physical entrapment has also been used in some studies to
place soluble proteins within a support for binding studies.105,106
Zonal elution is one method that has frequently been used with
HPAC columns to obtain information on the binding of solutes
to proteins or other agents.10,11,86 For instance, this combination
of techniques can be utilized for measuring the average affinity of
a drug or solute with an immobilized protein. In this type of
experiment, a small amount of a drug or solute is injected onto
a column that contains the protein of interest. The retention
factor (k) of the drug or solute is then calculated by using the
observed retention time and the column void time. This retention
factor can then be related to the bound fraction (b) and the free
fraction (f) of the drug through the expression k ¼ b/f, provided
a local equilibrium and linear elution conditions are present.7,10 It
is possible from this relationship to determine either the value of
b or f given the fact that the sum of the bound plus free fractions
for the drug must always be equal to one.107
This zonal elution approach has been used with various
coumarin compounds and HSA to compare the overall extent of
solute-protein binding that is measured by HPAC versus ultrafiltration.108 The same method has been used with other pharmaceuticals,109 including anti-HIV chemotherapy drugs,110 and
has been combined with LC/MS for the simultaneous examination of the protein interactions of several drugs in a mixture.107
Related reports have used k as a direct measure of the global
affinity of injected solutes for an immobilized protein. This
approach has been utilized to compare immobilization methods
and columns containing AGP or HSA for applications such as
binding studies or chiral separations involving R/Swarfarin,102,103 R/S-propanolol102 and D/L-tryptophan.103 This
technique has also been used for screening bioactive compounds
from plants by employing immobilized b2-adrenoceptors.111
A number of other HPAC studies have used measurements of
k to see how the mechanism of analyte retention changes on an
immobilized serum protein when factors such as the pH, ionic
strength or organic content of the mobile phase are
varied.10,112–120 A related set of applications have involved the use
of retention factor measurements for a series of structurallyrelated compounds on the same column to learn about binding
1454 | Anal. Methods, 2011, 3, 1449–1460

sites and to see how changes in the structure of a drug can affect
its interaction with a protein. This approach has been employed
to examine the binding of L-thyroxine, warfarin, coumarins,
sulfonylurea drugs and several indole compounds to HSA and
glycated HSA.121–126 Several studies involving a large set of
samples have used this method to develop quantitative structureretention (or reactivity) relationships (QSRRs) to describe drugprotein interactions.127–129 As an example, QSRR models have
been created with this technique to describe the binding of HSA
to benzodiazepines and 2,3-substituted-3-hydroxy-propionic
acid130,131 and to study the stereoselective interactions of AGP
with amino alcohols, antihistamines, beta-adrenolytic drugs,
cyclic
vinca
alkaloid
analogues,
and
quinazolone
derivatives.132–136
The most common application of zonal elution and HPAC in
the study of drug-protein interactions is the use of these methods
to investigate the competition and displacement of drugs from
proteins by other drugs or solutes.10 In this type of experiment,
a small pulse of one analyte is injected on an HPAC column
containing the immobilized protein while a fixed concentration
of a potential competing agent is passed through the column in
the mobile phase. Fig. 5 illustrates such an experiment, in which
the drug tolbutamide is used as a mobile phase additive on
a glycated HSA column and R-warfarin is injected as a siteselective probe for Sudlow site I on the immobilized protein.126
The shift in the chromatograms in Fig. 5(a) for R-warfarin as the
concentration of tolbutamide is increased indicates that these
two drugs interact on the immobilized protein. When the
measured retention data are plotted and analyzed according to
the plot shown in Fig. 5(b), it is possible to show that this
interaction involves direct competition at a common site. It is
also possible from this graph to determine the association equilibrium constant for tolbutamide at Sudlow site I. Other examples of this approach include reports that have examined the
displacement of D/L-thyronine and D/L-tryptophan by bilirubin
or caprylate from HSA;137 the competition of warfarin with
oxazepam, larazepam and hemisuccinate derivatives on a HSA
column;138 the competition of octanoic acid with oxazepam
hemisuccinate, ketoprofen A/B and suprofen A/B on HSA;139 the
competition of b-estradiol with progesterone on HSA;140 and the
site-specific interactions of sulfonylurea drugs with both normal
HSA and glycated HSA.125,126,141

6. Frontal analysis in HPAC
Another common technique that has been used for studying
drug-protein interactions by affinity chromatography and
HPAC is frontal analysis.7,10,142 Frontal analysis was first utilized
to study biological interactions by means of low-performance
affinity chromatography in 1975.143 This technique was then used
to examine the binding of salicylate with HSA144 and the binding
of fatty acids and drugs to BSA.145 The combined use of frontal
analysis with HPAC and HSA was later reported in the early
1990s.94,95,99,139
Frontal analysis in affinity chromatography and HPAC is
performed by continuously applying a known concentration of
a drug or analyte to a column that contains an immobilized
binding agent.7,10 As the immobilized agent becomes saturated by
the applied substance, the remaining drug or analyte in the
This journal is ª The Royal Society of Chemistry 2011

the binding of various sulfonylurea drugs and site-specific probes
to HSA and glycated HSA.124,126,141 Frontal analysis has also
been used to study the binding of R/S-propranolol and carbamazepine with AGP, as well as the binding of R/S-propranolol
and imipramine with HDL.147,148
When used in binding studies, the data from a frontal analysis
experiment are typically analyzed according to various models.
An example of such a comparison is given in Fig. 6(b) for the
binding of tolbutamide to HSA. Similar plots can be employed to
examine the fit of single-site or multi-site models to frontal
analysis data.10,149 These fits can often be used to determine both
the equilibrium constants and number of binding sites for a drugprotein interaction.7,10,149 For example, this approach has been
used to examine the changes in both the association equilibrium
constants and number of binding sites for D- and L- tryptophan
on immobilized HSA under various pH conditions.100 Similar
work has been carried out to examine the changes in binding
affinity and capacity that accompany the interactions of R/Swarfarin, D/L-tryptophan and carbamazepine with immobilized
HSA at a variety of temperatures.95,100,150 In such studies it has
been shown that shifts in retention with temperature can correspond to a change in either the number of available binding sites
or to changes in the affinity of an applied analyte for an immobilized binding agent.95,100,150–152
Fig. 5 (a) Typical chromatograms obtained in a zonal elution study on
a column containing glycated HSA and examining the competition
between injected samples of R-warfarin (i.e., a probe for Sudlow site I of
HSA) and tolbutamide, which was used here as a mobile phase additive.
The mobile phase concentrations of tolbutamide in (a) were (from top-tobottom) 20, 15, 10, 5 and 1 mM. The plot in (b) shows how the reciprocal
of the measured retention factor for R-warfarin (1/kR-Warfarin) changed as
the mobile phase concentration of tolbutamide was varied. The inset
equation shows the result that would be expected for 1 : 1 competition of
the injected analyte (A) and the mobile phase additive (I), in which KaA
and KaI are the association equilibrium constants for the analyte and
mobile phase additive at their site of competition, [I] is the mobile phase
concentration of I, mL represents the total moles of these binding sites,
and VM is the void volume of the column. Adapted with permission from
ref. 126.

mobile phase is allowed to pass through the column. This process
results in a breakthrough curve, as shown in Fig. 6(a). If relatively fast association and dissociation kinetics are present for
this system, the mean position of the breakthrough curve can be
related to the concentration of the applied analyte and used to
determine the affinity and the number of binding sites for the
analyte on the immobilized agent.7,10,142 A major advantage of
using frontal analysis and affinity chromatography or HPAC to
study drug-protein binding is that both the equilibrium constants
and binding capacities for these interactions can be determined
simultaneously.
Frontal analysis in HPAC has been utilized to investigate the
binding of HSA to R- or S-warfarin94,95 and D- and L-tryptophan.94,99,100,139 Another application of frontal analysis has been
the use of this method to determine the binding capacities of
monomeric vs. dimeric HSA for salicylic acid, warfarin, phenylbutazone, mefenamic acid, sulphamethizole and sulfonylurea
drugs.146 In addition, frontal analysis has been used to examine
This journal is ª The Royal Society of Chemistry 2011

7. Methods for kinetic analysis
There are several ways in which affinity chromatography, and
particularly HPAC, can be adapted for use in examining the
kinetics of a drug-protein interaction.7,10,90,154 One approach for
this type of study is to use band-broadening measurements, as
occurs in the plate height method. In this approach, the total
plate height for an analyte is measured on both an affinity
column that contains the immobilized binding agent and on an
otherwise identical control column that contains no binding
agent. These plate heights are then plotted as a function of flow
rate or linear velocity and used to find the plate height contribution due to stationary phase mass transfer (Hk). This value, in
turn, can then be plotted as a function of the linear velocity and
used to determine the dissociation rate constant between the
analyte and the immobilized binding agent.154
The plate height method has been utilized to examine the
association and dissociation kinetics of R/S-warfarin and D/Ltryptophan with HSA.96,153 This approach has further been used
to examine the effects of changes in various reaction conditions
(e.g., pH, temperature and organic modifier content of the
mobile phase) on the chiral separation of R/S-warfarin or D/Ltryptophan on HSA columns.96,153 It has been shown that this
technique can be used for systems with weak-to-moderate
binding (i.e., Ka # 106 M1) in the presence of linear elution
conditions.10,154
One variation on band-broadening measurements is the peak
profiling method.154 In this technique, which is illustrated in
Fig. 7, retention times and peak widths are measured on an
affinity column for both the analyte and for a non-retained
species; these measured values are then used to determine the
kinetics of analyte dissociation from the immobilized binding
agent by using the data for the non-retained species to correct for
other band-broadening processes.155,156 The peak profiling
Anal. Methods, 2011, 3, 1449–1460 | 1455

prevent re-association of the analyte as it dissociates from the
immobilized ligand. As the analyte dissociates under these
conditions, it is eluted from the column and produces a decay
curve. If the rate of stagnant mobile phase mass transfer rate is
fast compared to the rate of analyte dissociation, the slope of the
decay curve can be used to provide the dissociation rate constant
for the analyte from the immobilized binding agent.158–160
The peak decay method has been used in recent studies to
determine the dissociation rates of various drugs from
HSA.158,159 It has been found that this method works best at high
flow rates, which has made it of interest as a tool for the highthroughput screening of drug-protein dissociation rates.159,160

8. Recent trends and developments

Fig. 6 (a) Breakthrough curves obtained during frontal analysis studies
for tolbutamide on an HPAC column containing glycated HSA. The
applied concentrations of tolbutamide were (from left-to-right) 200, 100,
50, 20, and 10 mM. The graph in (b) shows a double-reciprocal plot that
was used to examine the frontal analysis results for tolbutamide with the
glycated HSA column. The inset equation shows the result that would be
expected for single-site binding between an applied analyte and an
immobilized binding agent, in which [A] is the concentration of the
applied analyte, Ka is the association equilibrium constant for the analyte
with the binding agent, mL is the total moles of binding sites involved in
these interactions, and mLapp represents the moles of analyte needed to
reach the mean position of the breakthrough curve. In this particular
example, deviations from a linear response occur at low values of
1/[Tolbutamide], indicating that multi-site interactions are present for
this system. Adapted with permission from ref. 126.

method can be carried out by using data collected at a single,
high flow rate;155 however, work at multiple flow rates tends to
result in more robust and accurate estimates of dissociation rate
constants.156
The peak profiling method has been utilized to examine the
dissociation of L-tryptophan from HSA, as well as the dissociation of carbamazepine and imipramine.156,157 In addition, this
technique has been modified for work with multi-site systems,
such as those in which a drug has significant binding to both an
immobilized protein and a support.157
Another approach that has been used to obtain information
on the kinetics of drug-protein interactions is the peak decay
method.158–160 This technique is conducted by first injecting
a pulse of the analyte onto a small affinity column. A mobile
phase is then applied to the column under conditions that
1456 | Anal. Methods, 2011, 3, 1449–1460

Given the wealth of information that HPLC can provide on
drug-protein binding, it is not surprising that these methods have
recently been explored as a means for the high-throughput
screening and analysis of these interactions. Examples were
provided in the previous section during the discussion of kinetic
measurements by HPAC.159,160 There have also been several
studies that have examined the use of chromatographic methods
in estimating or determining the affinities of drug-protein
systems. For instance, frontal analysis-mass spectrometry using
HPAC columns has been described as an approach for screening
drug candidates for a given target.161 An HSA column operated
under gradient elution conditions has been described for rapidly
examining the binding of various drugs with this serum
protein.162 In addition, frontal analysis and zonal elution have
been used to quickly examine the interaction of various drugs
with HSA by using a standard plot of retention factors and
association equilibrium constants for reference compounds to
determine the association equilibrium constants for other drugs
with HSA.163
The search for faster HPLC methods has, in turn, led to the use
of alternative supports such as monolithic columns for drugbinding studies.160,164,165 This type of application typically makes
use of the good mass transfer properties of monolithic supports
and their low back pressures, which allows such materials to
provide efficient separations at high flow rates.89 It has been
shown in one study that affinity monoliths based on a copolymer
of glycidyl methacrylate and ethylene dimethacrylate (also
known as GMA/EDMA monoliths) can be used for the ultrafast
immunoextraction of fluorescein. In this case, a 4.5 mm i.d. 
0.95 mm monolith disk containing anti-fluorescein antibodies
provided up to 95% extraction of fluorescein within 100 ms.164
The speed of this approach has made this type of support useful
in the direct analysis of free drug fractions in clinical samples, as
described in Section 2.
Related work has examined the use of several immobilization
methods for the preparation of GMA/EDMA monolithic
columns containing HSA. It has been found that the Schiff base
method provides for the greatest amount of immobilized HSA
and results in the best stereoselectivity and retention for R/Swarfarin and D/L-tryptophan.165 Affinity silica monoliths containing HSA or AGP have also been used for chiral separations
and in drug-protein binding studies.166,167 Affinity silica monoliths containing immobilized AGP have been used for the chiral
separation of R/S-warfarin and R/S-propranolol, while the chiral
This journal is ª The Royal Society of Chemistry 2011

Fig. 7 Use of the peak profiling method to examine the dissociation rate of L-tryptophan from HSA. The chromatograms in (a) and (b) were used to
provide the total plate heights HR and HM at several flow rates for L-tryptophan and sodium nitrate (i.e., a non-retained solute), respectively, on an HSA
column. These results were then examined by using a plot like the one shown in (c) to determine the dissociation rate constant (kd) for L-tryptophan from
HSA. The equation shown in the inset indicates that this type of plot should have a linear response with a slope that is inversely related to kd. Other terms
in this equation include the retention factor (k) for the retained analyte and the linear velocity (u). The value of Hk represents the plate height
contribution due to stationary phase mass transfer in the column. Adapted with permission from ref. 156.

separation of R/S-warfarin, D/L-tryptophan, and R/S-ibuprofen
have been carried out by using a HSA silica monolith column. In
each of these situations, silica monolith columns have been found
to give better resolution, stereoselectivity, and efficiency when
compared to columns that contain the same serum proteins on
silica particles or within GMA/EDMA monoliths.102,167
Other reports have examined the use of affinity microcolumns
that contain either silica monoliths or silica particles in drugbinding studies. The initial goal of this work has been to determine if these columns can be used in place of more traditional
HPAC columns for the examination of drug-protein binding by
methods such as frontal analysis or zonal elution. One study used
immobilized HSA in silica monolith microcolumns with lengths
of 1–5 mm for drug-protein binding studies. These microcolumns
were tested by using them to measure the retention factors and
plate height measurements for warfarin and carbamazepine in
the presence of the immobilized HSA. It was found that these
silica monolith affinity microcolumns could be used to produce
reliable estimates of retention factors and plate heights while
decreasing the analysis times that are needed for such measurements down to 10 s or less when using a 1 mm long microcolumn.102 In addition, it has been shown that affinity silica
monoliths as small as 1 mm  4.6 mm i.d. can be used in the peak
decay method to estimate dissociation rate constants for drugs
from immobilized HSA.160
Affinity microcolumns based on silica particles have also been
used with immobilized HSA to perform zonal elution and frontal
analysis studies.168 In this work, warfarin and L-tryptophan were
used as model analytes because these two solutes are commonly
This journal is ª The Royal Society of Chemistry 2011

used as site-specific probes for HSA. It was found that affinity
microcolumns as short as 1 mm that contained silica particles
could provide comparable results to those obtained with much
longer HPAC columns, while significantly decreasing the
analysis times and amount of protein needed for such experiments. It was concluded that these features make affinity
microcolumns based on either silica particles or silica monoliths
attractive for the rapid analysis of drug-protein interactions.168
The use of smaller columns may not only make it possible to
increase the speed of existing HPLC methods for drug-protein
binding studies, but these microcolumns create new opportunities for this type of work. For instance, Section 2 described the
use of small immunoextraction columns for the isolation and
measurement of free drug fractions.40–44 Another recent report
examined the use of affinity microcolumns containing immobilized HSA as tools for measuring free drug fractions in samples
that contained soluble HSA.169 In this method, a mixture containing a drug and the protein of interest was injected onto an
HSA affinity microcolumn. This injection was carried out at
a sufficiently high flow rate to minimize dissociation of the drug
from the protein as the sample passed through the HSA microcolumn. Under these conditions, a non-retained peak for the
drug-protein complex first elutes from the column, followed later
by a second peak that represents the free drug fraction that was
extracted and retained by the column (see Fig. 8). It was found
with this method that greater than 95% extraction could be
obtained within 250 ms for the free drug fractions, with this
fraction then being separated from the drug-protein complex in
the sample. This fraction was then eluted as a separate peak
Anal. Methods, 2011, 3, 1449–1460 | 1457
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Fig. 8 Chromatograms obtained using ultrafast affinity extraction and
a 4.5 mm  2.1 mm I.D. HSA microcolumn. These chromatograms were
obtained by injecting (a) 10 mM R-warfarin onto an HSA microcolumn, (b)
20 mM HSA plus 10 mM R-warfarin onto an HSA microcolumn, or (c) 20
mM HSA plus 10 mM R-warfarin onto a control column at 4.5 mL/min.
The non-retained peaks represent the HSA and complex between
R-warfarin and HSA in the injected sample. The second, retained peak
represents the free fraction of R-warfarin in the injected sample. Reproduced with permission from ref. 169.

under isocratic conditions within 40 s. This method was used
with soluble HSA and several drugs, including R-warfarin,
S-warfarin, S-ibuprofen, and imipramine, with association
equilibrium constants that ranged from 103–105 M1 for HSA.
This approach was found to give binding parameters that gave
good agreement with values obtained by reference methods such
as ultrafiltration and equilibrium dialysis.169
Another area of ongoing research has been the creation of new
mathematical tools and methods for data analysis that have
made it possible to expand the types of information on drugprotein binding that can be obtained by HPLC. A good example
is a recent method that has been described for the examination of
allosteric binding.170–172 This method can be used with zonal
elution and competition or displacement studies that are carried
out by HPAC. In this method, the retention factors for an analyte are measured in the presence of an immobilized binding
agent and in the presence (k) or absence (k0) of known concentrations of a competing agent (I) that may have either direct
competition or allosteric competition with the analyte. A plot is
then made of the term k0/(k-k0) versus 1/[I], which can be used to
determine if direct competition or allosteric interactions are
present. If allosteric interactions are found to occur, the same
plot can be used to measure the coupling constant for the effect
of the competing agent on the analyte.170–172 Other examples of
recent developments in the use of chromatography to study drugprotein binding are the extension of this general approach to
examine systems with multi-mode interactions (e.g., the binding
of a drug with a lipoprotein or multi-site binding of a drug with
a protein)104,124–126 and experiments that consider the effects of
multiple factors (e.g., protein modification and the presence of
fatty acids) on this type of binding.173
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